hVIVO (LON:HVO) Announces Quarterly Earnings Results

hVIVO (LON:HVO) issued its earnings results on Tuesday. The company reported GBX (0.82) earnings per share for the quarter, Digital Look Earnings reports. hVIVO had a negative return on equity of 14.65% and a negative net margin of 12.48%.

hVIVO Price Performance

Shares of hVIVO stock opened at GBX 5.84 on Wednesday. The company has a market capitalization of £40.18 million, a price-to-earnings ratio of -6.71 and a beta of 1.69. The company has a quick ratio of 1.16, a current ratio of 1.63 and a debt-to-equity ratio of 38.75. The stock’s 50-day simple moving average is GBX 6.81 and its 200-day simple moving average is GBX 7.41. hVIVO has a 52 week low of GBX 4.30 and a 52 week high of GBX 11.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.